Turning profits with Dr. Clay Siegall

Recently, Dr. Clay Siegall was interviewed by Inspirely.com about his company, Seattle Genetics, and how he first made a break in the biotechnology industry. In this interview, Dr. Clay Siegall discusses how he acquired his first customer, what inspired him to start this company and join this industry, and how long it took for his business to turn a profit. He also discusses what he thinks defines a successful businessman and how he thinks that definition applies to himself.

 

Dr. Siegall helped co-found Seattle Genetics in 1998, and currently, serves as President and Chief Executive Officer, while also maintaining a position as Chairman of the Board of Directors. During his time with Seattle Genetics, Dr. Siegall has helped developed a number of antibody-based cancer therapies. These include treatments such as ADCETRIS (brentuximab vedotin), which is currently in the process of accelerated approval by the FDA in 2011.

 

Dr. Siegall has also managed to help secure more than $675 million in capital through both public and private financing. Allowing Seattle Genetics plenty of room to grow and continue their research uninhibited by monetary constraints. He believes that success is dependent upon an Entrepreneurs desire and willingness to consistently learn. As without development an Entrepreneur can become stagnant and be lacking in vision.

 

Before founding Seattle Genetics, Dr. Siegall worked with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997, and before that with the National Cancer Institute and the National Institute of Health from 1988 to 1991. Graduating from the University of Maryland with a Bachelors Degree in Zoology, Dr. Siegall received his Ph.D. in Genetics from George Washington University.

 

Currently, Dr. Siegall serves on the Board of Directors for Alder BioPharmaceuticals, which is a private biotech company. He also holds 70 publications and 15 patents to his name, making Dr. Siegall a recognizable and influential name inside the biotech industry.

 

Clay Siegall’s commitment to researching a cure for cancer is strong.

Dr. Clay Siegall heads his organization, Seattle Genetics, to forming major advances, in the study of treating cancer patients. Clay Siegall is the organization’s CEO and President, which he also co-founded, in 1998. Dr. Clay Siegall is the board’s chairperson and is celebrated for his focused interests in the advances that create progress, for the outlook of those, who are stricken with cancer. This interest, has been the main focus of his career, from the early phase of his interest into biomedical exploration. Dr, Siegall, is valued by his team, as a detailed and reliable worker, who consistently advances to bring his company, to obtaining a large sum of medical advances, in cancer treatment and establishing truly advanced methodologies for helping cancer survivors.

George Washington College, is the esteemed University where Dr. Siegall acquired his highly valued, Ph.D. During his extent at the University, Clay studied in the field of Genetics, in which he majored and started forming an amount of important vocational undertakings. At the start, when Dr. Siegall strove as a Senior Researcher, he worked very hard, with delight, at the Pharmaceutical Investigative Institute, of Bristol-Myers. Clay swiftly completed an endorsement to the appointment of Foremost Scientist, then, to the title of Staff Fellow. Clay also attained the rank of Biotechnology Fellow, while at the National Cancer Institution. These clear advances in his vocation, focused his interest onto creating an organization to help cancer survivors, Seattle Genetics. Their advances in the community have permitted their stock return values to triple, in 5 years.

Dr. Siegall is touted for his pledge to finding new cancer treatments, by making use of newly instituted methodologies. In 2011, his company, made the first antibody-drug conjugates, winning his company the FDA’s approval to continue with their efforts. Seattle Genetics ongoing growth, aids them to helping survivors of cancer, across the globe. Clay is lauded, for his helping Seattle Genetics, to establish an extra $1.2 billion, from charity, contributed by public and private benefactors. These fiduciary gifts, brought in new tools that benefit survivors of cancer, by requisitioning cutting-edge paraphernalia.

Dr. Clay Siegall: Finding A Cure.

Seattle Genetics was co-founded in 1998 by Clay Siegall Ph.D. for cancer research.. Dr. Siegall is currently the President, Chief Executive Officer and Chairman of the Board of Directors for Settle Genetics with their headquarters in Bothell Washington and has partners with many biotechnology and pharmaceutical companies over the years. Seattle Genetics has been able to create antibody -based therapies for cancer patients who needs were otherwise not being met. These treatments help reduce the toxic damage of chemotherapy and improve antitumor activity. Dr. Siegall studied at the University of Maryland where he received a Bachelor in Science than attending George Washington University where he received his PhD in Genetics. He has worked for several companies before he started Seattle Genetics such as the National Cancer Institute, National Institutes of Health and Bristol Myers Squibb Pharmaceutical Research Institute. Not only does Dr. Siegall research cancers but he has written over 70 published works and holds 15 patents.
Dr. Siegall has since joined Mirna Therapeutics as an outside director to its Board of Directors. This is a company that focuses on MicroRNA-based therapeutics which is an area of cancer research. Through this particular type of research they are able to better study the human genome and how miRNAs can function as “master-switches” in cells. Dr. Siegall’s first commercial product was ADCETRIS (brentuximab vedotin) which was approved in August 2011.

This particular product has been used to help treat more than 15,000 lymphoma patients globally. They are working with the FDA to get a Biologics License Application (BLA) so they can help Hodgkin Lymphoma patients who are at high risk of relapse or progression. He has helped secure more than $675 million through public and private financings. This has led to Seattle Genetics ability to conduct such prominent research. Dr. Clay Siegall is an important part in the research and advancement of treatments in the cancer field. With plans for other treatments in the works for different types of cancers there is no telling how far he will be able to push the envelope. One day hopefully “finding a cure for cancer”.

Original Article:

http://newschoolmagazine.com/index.php/category/clay-siegall/